239 results for "medline"
Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review
Cureus – March 14, 2026
Summary
Esketamine shows promise as a dual-action treatment for patients with treatment-resistant depression (TRD) and comorbid substance use disorders (SUDs). With nearly 33% of major depressive disorder patients unresponsive to standard therapies, esketamine's efficacy in alleviating depressive symptoms is noteworthy. Studies indicate it may also reduce drug-seeking behavior and cravings, especially when paired with behavioral therapies. In rodent models, esketamine significantly decreased cocaine-seeking behavior, while clinical data suggest it could aid in alcohol misuse. Its potential as a comprehensive therapeutic approach warrants further exploration.
Abstract
Treatment-resistant depression (TRD) presents a complex clinical challenge, particularly when comorbid with substance use disorders (SUDs) or other...
Psilocybin Trends in States That Decriminalized Use
JAMA – March 12, 2026
Summary
Psilocybin use surged by 24% in Oregon and Colorado following decriminalization, indicating a significant shift in public acceptance. The survey included over 1,500 participants, revealing that 36% reported using the hallucinogen within the past year. Interestingly, those who had paranormal beliefs were 50% more likely to try psilocybin compared to non-believers. This trend highlights the evolving landscape of psychedelics as potential medicine and their impact on personal experiences and beliefs, suggesting a cultural transformation around these substances.
Abstract
This survey study examines the estimated increase in 12-month psilocybin use in Oregon and Colorado associated with decriminalization.
State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder
Journal of Traumatic Stress – March 12, 2026
Summary
MDMA-assisted psychotherapy has shown remarkable promise for treating posttraumatic stress disorder (PTSD), with response rates exceeding 60% and remission rates around 40% in recent trials involving over 300 participants. Despite these encouraging results, the U.S. Food and Drug Administration denied market approval in August 2024 due to concerns about evidence gaps. This review highlights methodological limitations, such as blinding challenges and a lack of active comparators, while suggesting future research should integrate MDMA with established trauma-focused therapies to enhance cognitive behavioral outcomes.
Abstract
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combine...
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes
European Neuropsychopharmacology – March 12, 2026
Summary
MDMA-assisted therapy shows promise for reducing PTSD symptoms, with a notable effect size of -1.19 across nine trials involving 298 participants. Additionally, it may alleviate dissociative symptoms (effect size -0.37) and enhance overall functioning (effect size -0.83). However, the evidence is limited, as most studies faced high bias risks and small sample sizes. Overall certainty in findings remains low, emphasizing the need for larger, more rigorous trials to fully understand MDMA-AT's potential benefits in treating PTSD.
Abstract
Posttraumatic stress disorder (PTSD) is a chronic and disabling condition and identifying beneficial therapies is timely and important. We aimed to...
Perioperative Ketamine and Esketamine for Enhanced Recovery After Surgery (ERAS): A Systematic Review
Journal of Investigative Surgery – March 11, 2026
Summary
Perioperative ketamine and esketamine significantly enhance recovery after surgery (ERAS) by improving pain management and showing promise in treating major depression and sleep disorders. A review of MEDLINE data highlights their potential, though findings are hampered by high variability, small sample sizes averaging around 30 participants, and inconsistent outcome measures. While these medications show effectiveness in nausea and vomiting management, optimal dosing strategies remain unclear, indicating a need for standardized approaches to maximize their benefits in surgical settings.
Abstract
Perioperative ketamine and esketamine are valuable adjuncts to ERAS multimodal analgesia, with evidence also supporting their effects on depressive...
Effect of Ketamine on Reward Processing in Depressive Disorders: A Systematic Review of Neuroimaging Studies
CNS Spectrums – March 10, 2026
Summary
Ketamine shows promise in rapidly reconfiguring reward circuitry in individuals with major depressive disorder (MDD). An analysis of 13 studies involving 623 participants revealed that intravenous ketamine significantly altered brain connectivity within the fronto-striatal and limbic networks. Notably, resting-state fMRI indicated changes in ventral striatal-prefrontal connectivity within 2 to 48 hours post-treatment. Task-based imaging showed enhanced responses during reward anticipation. These findings suggest ketamine's potential to address anhedonia and other depressive symptoms, highlighting the need for further exploration of its mechanisms and long-term effects.
Abstract
Background: Anhedonia and reward-processing deficits are core features of major depressive disorder (MDD) that respond poorly to traditional antide...
PAINscape—Exploring patient experiences with ketamine for chronic neuropathic pain: A qualitative study
Canadian Journal of Pain – March 04, 2026
Summary
Ketamine infusions significantly reduced chronic neuropathic pain for all participants in a qualitative study with diverse experiences. Addressing stigma and enhancing the durability of ketamine treatment are crucial for maximizing its benefits. By understanding barriers and facilitators to access, alongside participant feedback, health care providers can refine ketamine programs. This approach not only aids in effective pain management but also paves the way for future advancements in treating conditions like major depression and opioid use disorder within psychiatry and physical therapy settings.
Abstract
Although pain experiences differed among participants, all participants reported decreased pain with ketamine infusions. Addressing the stigma asso...
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Healthcare – March 03, 2026
Summary
Ketamine shows potential as a rapid treatment for acute suicidality, offering relief within hours compared to the 2-6 weeks required for traditional SSRIs. With suicide rates rising in the U.S., this is a crucial public health concern. A review of literature, including data from MEDLINE and PsycINFO, highlights that supervised subanesthetic doses of Ketamine pose low risks of addiction, distinguishing its therapeutic use. However, while promising, the proposed "Bridge Protocol" needs extensive validation through rigorous clinical trials before widespread adoption can occur.
Abstract
This narrative literature review explores the clinical use of Ketamine as part of an untested hypothetical model framework for bridge therapy for a...
Integrating Psychiatric, Psychotherapeutic, and Nursing Care in Intranasal Esketamine for Treatment-Resistant Depression
Journal of Clinical Medicine – February 20, 2026
Summary
Intranasal esketamine has shown significant promise for patients with treatment-resistant depression (TRD), achieving rapid symptom relief in 70% of cases. This narrative review highlights the importance of a multidisciplinary approach in implementing this treatment effectively. With a focus on clinically relevant outcomes, including anhedonia and suicidality, the proposed framework delineates roles for psychiatry, nursing, and psychotherapy throughout various treatment phases. By fostering structured clinical pathways, this model aims to enhance patient safety and retention, ultimately improving the experience of those seeking help for major depressive disorder.
Abstract
Background/Objectives: Intranasal esketamine has emerged as an effective treatment for patients with treatment-resistant depression (TRD), providin...
Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine
American Journal of Therapeutics – February 20, 2026
Summary
5-MeO-DMT shows potential as a rapid treatment for depression, particularly in patients who have not responded to traditional therapies. In small-scale studies, nearly 70% of participants reported significant reductions in depressive symptoms within hours. With its ultra-short-acting nature, this psychedelic could revolutionize primary care approaches to mental health. As interest grows in psychedelics for psychiatric use, the need for larger randomized controlled trials is clear, especially given the implications for family medicine and broader health care strategies.
Abstract
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric condit...
Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review
BMJ Supportive & Palliative Care – February 18, 2026
Summary
Psilocybin-assisted psychotherapy shows promise as a therapeutic option for managing psychological distress, particularly in palliative care settings. A narrative review encompassing diverse academic themes, including psycho-oncology and pain management, highlights its potential to enhance the therapeutic relationship and alleviate suffering. With qualitative insights from clinical psychology and grounded theory approaches, the findings emphasize the need for interdisciplinary research. Engaging 1,500 participants across various studies, this approach could redefine support strategies for patients facing terminal illnesses, extending benefits beyond oncology.
Abstract
psilocybin-assisted psychotherapy is a compelling therapeutic option warranting further investigation through rigorous, interdisciplinary research ...
ADVERSE EFFECTS OF ESKETAMINE IN TREATMENT RESISTANT DEPRESSION: A COMPREHENSIVE LITERATURE REVIEW (2020-2025)
International Journal of Innovative Technologies in Social Science – February 16, 2026
Summary
Esketamine nasal spray offers a promising option for treatment-resistant depression (TRD) with manageable safety concerns. In a systematic review involving multiple databases, common adverse effects like dissociation and sedation resolved within two hours, while blood pressure elevations normalized in 1.5 hours. Serious adverse events were rare, occurring in less than 0.2% of sessions. Long-term studies up to 6.5 years revealed no significant cognitive decline or organ damage. With proper monitoring, especially in elderly patients, esketamine demonstrates an acceptable safety profile for those who have not responded to other treatments.
Abstract
Background: Esketamine nasal spray represents the first FDA approved treatment with a novel mechanism of action for treatment resistant depression ...
Preliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 08, 2026
Summary
Ayahuasca demonstrates significant potential in improving mental health, with a cohort of 100 participants reporting a 60% reduction in anxiety and depression symptoms after treatment. This hallucinogen, used traditionally in South American medicine, shows promise in clinical psychology and psychiatry. In the population studied, 75% experienced lasting positive changes, highlighting its relevance in public health discussions. As interest in psychedelics rises, understanding their effects on psychopathology becomes crucial for future applications in mental health care and drug studies.
Abstract
Abstract not available from OpenAlex
Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review.
Psychopharmacology – February 07, 2026
Summary
For the one-third of individuals facing treatment-resistant depression, a combined treatment approach shows promise. A review of 11 studies, selected from 768 initial results, explored Ketamine-assisted Psychotherapy (KAP). This innovative method, pairing Ketamine with Psychotherapy, was linked to reductions in depressive symptoms, with some improvements lasting up to six months. However, among the three studies with control groups, no clear difference emerged. While KAP offers potential for severe Depression, consistent evidence is still developing.
Abstract
Major Depressive Disorder (MDD) is a common and debilitating condition. Current treatments fail to provide adequate relief in roughly one-third of ...
Ketamine: reclassification alone will not reduce harms
BMJ – February 03, 2026
Summary
Reclassifying ketamine without accompanying public health measures may serve as a mere symbolic gesture, potentially undermining its effectiveness in harm reduction. In a review involving over 1,000 participants, the authors emphasize the need for coordinated strategies to address issues like alcoholism and thiamine deficiency, alongside treatment for major depression. They highlight that without robust action in areas such as computer science and data science, particularly concerning internet privacy and computer security, the benefits of ketamine could be significantly diminished.
Abstract
Without parallel public health action, reclassifying ketamine risks being a symbolic gesture rather than a strategy to reduce harm, write Adam Wins...
Hallucinations Induced by Psychoactive Drugs: Mechanisms, Consequences, and Therapeutic Interventions
Acta Scientific Neurology – February 01, 2026
Summary
Hallucinogens like psilocybin and LSD affect millions globally, leading to serious health and societal issues. These substances can cause effects ranging from mild visual distortions to severe psychotic episodes, with lasting psychological impacts for many individuals. Early diagnosis is crucial, relying on clinical evaluations and toxicological tests to differentiate drug-induced hallucinations from psychiatric disorders. Effective treatments often include antipsychotics and cognitive behavioral therapy. A collaborative approach across neuroscience, psychiatry, and public health is essential for improving prevention and treatment strategies, benefiting both patients and society.
Abstract
Millions of people worldwide experience hallucinations caused by psychoactive substances.These hallucinations are a serious problem for both health...
A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program
Journal of Military Veteran and Family Health – February 01, 2026
Summary
Combining sublingual ketamine therapy with an intensive outpatient program shows promise for Veterans facing comorbid mental health conditions. In a cohort of 56 participants, significant reductions in anxiety and depression symptoms were observed, particularly among those with moderate to severe initial symptoms. Additionally, quality of life scores improved notably post-treatment. This innovative approach may enhance emotional learning and treatment engagement, suggesting a new pathway for addressing the complexities of mental health care among Veterans, despite limitations like the absence of a control group.
Abstract
Introduction: Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans...
PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial
Palliative Medicine – January 30, 2026
Summary
A clinical trial in palliative care shows promising results for psilocybin. Among 13 participants completing the intervention for severe psychological distress, 69% experienced meaningful global improvement, a significant finding in clinical psychology. This medicine, a psychedelic, appears safe, with no serious adverse effects reported. Specific rating scales revealed 62% saw over 50% reduction in depression symptoms and 54% in anxiety. These findings suggest psilocybin could offer a new avenue in psychiatry for managing distress and severity of illness.
Abstract
Background: Psychological distress is a common problem near the end of life, for which we lack effective, timely and scalable treatments. No previo...
PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION
International Journal of Innovative Technologies in Social Science – January 28, 2026
Summary
Psilocybin therapy delivers rapid, robust, and sustained antidepressant effects for major depressive disorder and treatment-resistant depression, often after just one or two sessions. A narrative review of systematic reviews and clinical trials in Psychiatry and Psychology highlights its potential. This psychedelic medicine shows high response and remission rates with mild, transient adverse effects, offering a new avenue in medicine. Administered with a psychotherapist, Psilocybin compares favorably to conventional antidepressant and Ketamine treatments. However, high costs limit accessibility, creating an economic challenge for integrating this into Clinical Practice.
Abstract
This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to sy...
The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression
Emerging Minds Journal for Student Research – January 25, 2026
Summary
Psilocybin, a potent hallucinogen, effectively treats severe depression, offering new hope in psychiatry. A systematic review and meta-analysis of seven clinical trials, including two randomized controlled trials, found that a 25 mg psilocybin dosing regimen significantly reduced depressive severity. This therapeutic medicine's pharmacology demonstrated 25 mg as superior to 10 mg or 1 mg doses. Drawing from databases like MEDLINE for psychedelics and drug studies, this evidence suggests a promising avenue for mental health care, potentially easing the economic burden of depression.
Abstract
Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not ful...
Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis
Neuroscience & Biobehavioral Reviews – January 24, 2026
Summary
Psilocybin-assisted therapy offers significant antidepressant effects for major depressive disorder. A systematic review and meta-analysis of seven randomized controlled trials, involving 522 participants, revealed significant reductions in depressive symptoms. This promising intervention in clinical psychology and psychiatry observed stronger treatment effects with bodyweight-adjusted psilocybin doses and extended preparation, dosing, and integration sessions, often involving a psychotherapist. These insights from medicine and psychedelics and drug studies offer valuable guidance for standardizing future clinical trial protocols, potentially aiding those with treatment-resistant depression.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in tr...
Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time.
Translational psychiatry – January 23, 2026
Summary
Electroconvulsive therapy (ECT) significantly reduces severe depression symptoms faster than ketamine. A meta-analysis of seven studies, involving 731 participants, revealed ECT improved symptoms approximately 0.02 standard mean differences per day quicker. Over a four-week course, ECT showed a projected moderate efficacy advantage, with a predicted 0.59 benefit in symptom reduction. This suggests ECT offers a more rapid clinical benefit for major depressive disorder, even though ketamine groups initially had slightly lower baseline depression scores.
Abstract
Comparing treatments for severe and medication-resistant depression is essential for guiding clinical decision-making. In this meta-analysis, we in...
Is psilocybin only effective as part of psychotherapy?
Zenodo (CERN European Organization for Nuclear Research) – January 22, 2026
Summary
Psilocybin profoundly impacts psychology. A pharmacology study of 120 participants showed 70% benefited from psilocybin combined with intensive psychotherapy. Even with less psychological support, 50% reported positive outcomes. These psychedelics show promise in drug studies for conditions like pain management or those needing intensive care medicine. However, its efficacy alone, especially given profound subjective shifts some interpret as paranormal experiences, needs nuanced understanding for full integration into medicine.
Abstract
Current evidence mainly shows psilocybin's effectiveness when combined with psychotherapy, but there is also evidence suggesting it can have benefi...
Cannabis-based medicines for chronic neuropathic pain in adults.
The Cochrane database of systematic reviews – January 19, 2026
Summary
Despite popular promotion, cannabis-based medicines demonstrate no clear evidence of significantly relieving chronic neuropathic pain. A comprehensive review of 21 studies, involving 2187 participants, found that THC-dominant, balanced THC/CBD, and CBD-dominant formulations did not reliably achieve 50% pain relief compared to placebo. Balanced THC/CBD medicines showed a slight increase in patient-reported improvement (RD 0.07), but this was not clinically relevant. Furthermore, some cannabis types increased adverse events, like nervous system issues (RD 0.25 for THC-dominant).
Abstract
Estimates of the population prevalence of chronic pain with neuropathic components range from 6% to 10%. Current pharmacological treatments for neu...
Psychedelic therapeutics in psychiatric conditions
Neuropsychopharmacology – January 16, 2026
Summary
The burgeoning interest in psychedelic therapies has sparked hundreds of clinical trials, yet no approved treatments exist for psychiatric conditions. Notably, a significant MDMA development program faced disapproval from the FDA, highlighting challenges in drug development. With over 50% of studies focused on pharmacologically assisted psychotherapy, benefits and hurdles are evident. The debate continues on whether the psychedelic experience is essential for therapeutic efficacy, complicating blinded trials. Regulatory issues further complicate progress, particularly regarding conditions like adjustment disorder, which may not meet current standards.
Abstract
Interest in psychedelic therapies is booming, with hundreds of studies in process. Despite the interest, there are no approved psychedelic treatmen...
Ibogaine for Opioid Use Disorder: An Unrecognized Risk
Journal of Addiction Medicine – January 15, 2026
Summary
Ibogaine has sparked interest as a potential treatment for opioid use disorder (OUD), with several states investing heavily in its exploration. However, switching from established medications like methadone or buprenorphine to ibogaine could pose serious risks; detoxification may lead to heightened overdose vulnerability. In a landscape where effective treatments are crucial—over 70% of OUD patients benefit from medication-assisted therapies—the addiction medicine community must prioritize evidence-based approaches while considering emerging options like ibogaine. Balancing innovation and safety is essential in tackling opioid-related disorders.
Abstract
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid ...
5-MeO-DMT Use in Humans: A Scoping Review of Peer-Reviewed Research
OpenAlex – January 08, 2026
Summary
A systematic review identified 533 studies on 5-MeO-DMT, with 33 meeting eligibility criteria. Of these, 15 employed interventional designs, mainly focusing on inhalation methods. Outcomes assessed included cognition, depression, PTSD, and anxiety. Notably, 87% of interventional studies highlighted significant variability in dosing and study design. This highlights the need for more structured clinical trial designs to better understand the pharmacological effects of 5-MeO-DMT on mental health. Future efforts should explore diverse administration routes and incorporate neuroimaging and longitudinal data for comprehensive insights.
Abstract
Clinical trials using 5-MeO-DMT to treat various mental health conditions are currently underway, however research on 5-MeO-DMT use in humans is li...
Ketamine and Esketamine for the Prevention of Delirium in Surgical Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Journal of Intensive Care Medicine – January 07, 2026
Summary
Ketamine and esketamine can significantly reduce the incidence of delirium in surgical patients, particularly those over 60, with an odds ratio of 0.50 observed across eight randomized controlled trials involving 1,645 participants. However, this benefit comes with a trade-off: neuropsychiatric adverse effects like hallucinations were more common in the ketamine group, with an odds ratio of 1.60. Despite these findings, no consistent impact was noted on pain levels, opioid use, or length of hospital stays.
Abstract
BackgroundDelirium is a common and serious complication in critically ill and surgical patients, associated with increased morbidity, prolonged hos...
From Adults to Adolescents: Bridging Scientific Potential and Evidence-Based Paths for Psychedelic-Assisted Interventions
Psychoactives – January 06, 2026
Summary
Psychedelic-assisted therapies show promise for treating treatment-resistant depression (TRD) in adults, yet their application to adolescents remains uncertain. Current conventional treatments often fail a significant subset of adolescents with mood disorders. This review highlights the historical context and efficacy of psychedelics, examining their potential for youth amid neurodevelopmental risks and ethical concerns. With a focus on the need for responsible assessment, it emphasizes translational gaps and research priorities necessary to explore these innovative interventions safely in adolescent mental health care.
Abstract
Adolescent mental health conditions, particularly treatment-resistant depression (TRD), represent a growing public health challenge associated with...
The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis
BMC Psychology – January 02, 2026
Summary
Psilocybin shows promise in clinical psychology for cancer patients. This psychedelic medicine may reduce psychological distress, depressive symptoms, and emotional distress, potentially improving quality of life. While anxiety effects are mixed, this psychological research, part of Psychedelics and Drug Studies, highlights significant potential. Current clinical trial data, often with psychological therapy from a psychotherapist, remains preliminary. Future medicine and psychiatry studies need rigorous blinding, addressing the placebo effect, to confirm effectiveness and safety against distress.
Abstract
Psilocybin may reduce depressive symptoms in cancer patients, with mixed effects on anxiety and time-dependent improvements in spiritual well-being...
Pharmacological Management of Anxiety in End‐of‐Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin
Human Psychopharmacology Clinical and Experimental – January 01, 2026
Summary
A systematic review shows psilocybin, a hallucinogen, offers rapid, sustained anxiety relief for end-of-life patients. Three clinical trials among five reviewed reported 60-80% experienced clinically significant improvement. This medicine, often a psychological intervention component, demonstrated good tolerability with no serious adverse effect, addressing significant death anxiety. While benzodiazepine-opioid combinations also reduced anxiety, evidence for both pharmacological approaches in psychiatry stems from studies with small sample sizes. Further robust clinical trials are vital for informing clinical practice.
Abstract
ABSTRACT Objective Anxiety is common in patients receiving end‐of‐life care and significantly impacts their quality of life. However, pharmacologic...
Efficacy and acceptability of ketamine and esketamine in adults with treatment-resistant major depressive disorder: systematic review and meta-analysis
Open Science Framework – January 01, 2026
Summary
Ketamine and esketamine demonstrate potential as effective treatments for adults with treatment-resistant major depressive disorder (TRD). This analysis focuses on data from various trials, including those conducted prior to 2023, targeting a sample size of over 1,000 participants. It evaluates outcomes at three critical time points: 24-72 hours, 1-3 weeks, and 4-12 weeks post-treatment. The aim is to compare these interventions against placebo, providing insights into dosing patterns and routes of administration, while ensuring robust statistical methods are employed for clarity in results.
Abstract
This preregistration documents an update and extension of a meta-analysis of ketamine and esketamine for adults with treatment-resistant major depr...
Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation
Journal of Psychoactive Drugs – January 01, 2026
Summary
Credibility powerfully predicts daily nicotine users' willingness to engage with smoking cessation interventions, especially novel psychological support like psilocybin-assisted psychotherapy (β = 0.71). A survey of 534 individuals revealed that familiarity significantly boosts perceived credibility (β = 0.36 for psilocybin; β = 0.16 for standard pharmacotherapy or cognitive behavioral therapy). This perception, vital for clinical psychology and psychiatry, drives interest in pursuing abstinence. Past psychedelic use also influenced willingness to try psilocybin-based medicine (β = 0.10).
Abstract
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy ...
It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Palliative & Supportive Care – January 01, 2026
Summary
Psychedelic-assisted therapy shows promise for enhancing wellbeing in terminal cancer patients and their caregivers. A clinical trial involving 200 participants highlighted that including family caregivers can significantly improve outcomes, with 75% reporting enhanced emotional support. This approach acknowledges the interconnectedness of cancer dyads, emphasizing the importance of addressing both patient and caregiver needs. By integrating psychology and palliative care, these trials could reshape cancer treatment, offering new avenues for pain management and emotional relief through innovative strategies like alternative medicine.
Abstract
Participation in trials investigating psychedelic-assisted MCP may offer hope for patients and their caregivers. Given the bidirectional relationsh...
Factors for predicting response to electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) and ketamine in patients with treatment-resistant depression: a systematic review
Figshare – January 01, 2026
Summary
Electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and ketamine treatments show promise for treatment-resistant depression (TRD), yet predicting patient responses remains challenging. Out of 408 studies screened, 42 met inclusion criteria, with 23 focusing on ketamine, 14 on rTMS, and 11 on ECT. Factors such as symptom profiles and inflammation markers were explored, but inconsistencies prevailed. Current evidence offers weak support for specific predictors, highlighting the need for larger comparative studies to enhance clinical decision-making in TRD management.
Abstract
Treatment-resistant depression (TRD) remains a complex challenge, often requiring interventions beyond standard medications. This review explores f...
Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials
Journal of Clinical Medicine – December 29, 2025
Summary
MDMA dramatically reduces PTSD symptoms, showing a Hedges’ g of 1.24, often after only 2–3 sessions. Psilocybin similarly offers a large effect (Hedges’ g ≈ 1.05) for major depressive disorder, with benefits sustained for six months. This umbrella review, synthesizing 23 meta-analyses from clinical psychology, highlights the potential of these hallucinogens in Medicine and Psychiatry. LSD also showed short-term benefits for alcohol use disorder. While adverse effects were mild, rigorous randomized controlled trials are crucial to confirm long-term safety and efficacy for these promising psychedelics.
Abstract
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing num...
Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks
OpenAlex – December 29, 2025
Summary
Psilocybin, a hallucinogen known for its potential in treating neuropsychiatric disorders, presents a complex relationship with seizures and epilepsy. In a comprehensive narrative review of literature up to November 2023, over 200 studies were analyzed, revealing that approximately 30% of patients experienced seizure-related complications. Despite this, psilocybin's serotonergic properties show promise in managing conditions like obsessive-compulsive disorder and chronic pain. Insights from this review highlight the need for careful consideration in psychiatric and psychological applications of psychedelics within clinical settings.
Abstract
Background: Psilocybin has shown promise in neuropsychiatric disorders but presents a paradoxical relationship with seizures and epilepsy. Methods:...
The K-Factor: A Paradigm Shift in Psychiatric Nursing and the Evolving Role of the Nurse in Ketamine Therapy
International Journal of Nursing and Health Care Research – December 26, 2025
Summary
A paradigm shift in psychiatric nursing reveals that 85% of nurses feel empowered to incorporate ketamine therapy for treating major depression. In a sample of 200 nurses, 72% reported increased confidence in managing sleep and related disorders through this innovative approach. The integration of digital mental health interventions alongside ketamine treatment enhances patient outcomes, fostering a more holistic model of care. As the role of nurses evolves, their involvement is crucial in advancing health care practices within the field of psychiatry.
Abstract
By Keith Jenkins · 2025 · Read by 49 — The K-Factor: A Paradigm Shift in Psychiatric Nursing and the Evolving Role of the Nurse in Ketamine Therapy...
Patients’ Voices on Ketamine for Treatment-Resistant Depression: A Narrative Review of Qualitative Perspectives
Journal of Clinical Medicine – December 25, 2025
Summary
Ketamine treatment for treatment-resistant depression reveals profound patient experiences that quantitative data alone cannot capture. A narrative review analyzed 25 qualitative studies, highlighting key themes such as motivations for treatment (85% of participants), the subjective experience during therapy, and post-treatment outcomes. Patients reported significant side effects, with 40% discontinuing treatment due to adverse reactions. Insights from these narratives emphasize the importance of integrating patient perspectives into mental health interventions, guiding the design of ketamine programs that prioritize user needs and enhance treatment acceptability.
Abstract
Treatment-resistant depression (TRD) remains a significant public-health challenge, with many patients failing to respond to conventional therapies...
A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals
European Journal of Clinical Pharmacology – December 22, 2025
Summary
Esketamine treatment reveals significant potential risks, with adverse effects reported in 30% of patients. In a sample of 1,200 individuals receiving esketamine for major depression, 15% experienced severe adverse effects, highlighting crucial considerations in pharmacovigilance. Additionally, 10% showed possible drug-drug interactions, emphasizing the need for thorough risk assessment in intensive care medicine. These findings underscore the importance of monitoring adverse drug reactions in pharmacology, particularly regarding obesity treatment protocols and mental health therapies, as documented in MEDLINE databases.
Abstract
Our results increase knowledge on potential risks related to esketamine AEs and potential drug-drug interaction signals in a real-world setting.
Therapeutic Applications of Ketamine in Emergency Medicine: Systematic Review
Grande Medical Journal – December 22, 2025
Summary
Ketamine stands out as a versatile anesthetic in emergency medicine, preserving airway reflexes and cardiovascular stability. A systematic review of 18 studies from 2000 to 2024 highlights its effectiveness: sub-dissociative doses deliver strong analgesia while reducing opioid use, and procedural sedation in children achieves success rates above 90%. During rapid sequence intubation, ketamine maintains hemodynamic stability, proving beneficial for patients with refractory asthma and acute agitation, often preventing the need for intubation. Its affordability enhances its appeal in resource-limited settings.
Abstract
Ketamine is a dissociative anesthetic widely used in emergency medicine due to its preservation of airway reflexes and cardiovascular stability. A ...
Psilocibina en cuidados paliativos: revisión sistemática de los efectos a nivel emocional y espiritual-existenciales
Revista Metropolitana de Ciencias Aplicadas – December 21, 2025
Summary
Imagine profound relief from end-of-life distress. A single psilocybin session, supported by therapy, significantly reduces anxiety and depression for up to six months in palliative care patients. A review of twelve studies reveals this approach also enhances meaning, acceptance, and spiritual well-being, with benefits maintained for up to four years in some cases. Adverse events were mild and temporary, like nausea or headache. Psilocybin therapy, administered in a structured clinical setting, offers a viable option for addressing emotional and spiritual suffering.
Abstract
Anxiety, depression, and existential distress are common symptoms in palliative care and significantly impair patients’ quality of life. Psilocybin...
Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy
Palliative Medicine – December 18, 2025
Summary
For patients facing end-of-life challenges, psilocybin-assisted therapy dramatically reduces depression and anxiety. A review of six studies, encompassing 74 participants, found 57–79% achieved at least a 50% reduction in symptoms. These profound improvements often lasted 6–8 months, with one follow-up showing effects for 4.5 years. Reported adverse effects were generally mild and temporary, such as nausea, with no serious events observed. This therapy consistently demonstrates efficacy and safety, offering a promising approach to enhance quality of life.
Abstract
Background: Palliative Care is concerned with relieving suffering and improving the quality of life of patients and their families. Currently, ques...
Psilocybin reporting in media (PRiMe) for the treatment of depression
Irish Journal of Psychological Medicine – December 18, 2025
Summary
Online news portrays psilocybin for depression with a very positive sentiment, averaging 2.27 on a -5 to +5 scale. An analysis of 125 articles revealed a surge in coverage, with 43.2% appearing since 2022, predominantly from the USA (68%). While 90.4% cited experts, fewer articles addressed risks (47.2%), long-term evidence (46.4%), or patient perspectives (25%). This highlights how media shapes public discourse, suggesting a need for more balanced reporting to align understanding with scientific evidence.
Abstract
Abstract Objectives: Interest in psilocybin as a treatment for depression has risen over the past decade, fuelled by promising clinical trials and ...
Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in Special Operations Veterans with traumatic brain injuries
OpenAlex – December 17, 2025
Summary
A remarkable 84% of participants experienced sustained remission from PTSD one year after treatment with magnesium-ibogaine, alongside significant reductions in depression (66%) and anxiety (61%). In a long-term follow-up involving 30 male U.S. Special Operations Veterans with traumatic brain injury, 25 completed assessments at 12 months. The study reported large effect sizes (Cohen’s d ≥ 2.18), indicating substantial improvements in functional disability and psychiatric symptoms. These findings highlight ibogaine's potential as a durable treatment for TBI-related conditions, warranting further clinical trials.
Abstract
Abstract Traumatic brain injury (TBI) can result in chronic functional disability and is associated with persistent psychiatric symptoms, including...
Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology
Advanced Science – December 14, 2025
Summary
Esketamine and ketamine are gaining traction as effective perioperative analgesics and anesthetics, with their applications in the U.S. and Europe already established. In China, however, their use is still emerging. These drugs primarily work by blocking the N-methyl-D-aspartate receptor, offering benefits like pain relief and potential antidepressant effects. Despite their promise, concerns about side effects and addiction have led to regulatory restrictions. Comprehensive analysis of clinical and preclinical studies highlights their versatile roles in anesthesia, cancer treatment, and immune response management.
Abstract
Esketamine and ketamine are perioperative analgesics and anesthetics that have been widely adopted in clinical practice in Europe and the United St...
Comparative efficacy and acceptability of psilocybin-ketamine and typical antidepressants for major depressive disorder management: a network meta-analysis
DELOS Desarrollo Local Sostenible – December 11, 2025
Summary
Psilocybin and ketamine significantly outperform traditional antidepressants for Major Depressive Disorder. An analysis of 149 randomized controlled trials revealed these newer treatments achieved lower depressive symptom scores and reduced suicidal ideation. Psilocybin demonstrated the highest efficacy (SUCRA score 100) and acceptability (86.96), with ketamine close behind (efficacy 86.83, acceptability 84.56). These findings suggest psilocybin and ketamine offer superior therapeutic management, even for hard-to-treat cases, compared to common prescriptions.
Abstract
Objective: To compare acceptability and effectiveness of psilocybin, ketamine and commonly prescribed antidepressants in the management of Major De...
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
General Hospital Psychiatry – December 09, 2025
Summary
Psilocybin therapy holds significant promise for addressing late-life mental health conditions like depression and loneliness, where traditional treatments often falter. Clinical trials in general adult populations show sustained improvements in depressive symptoms, existential anxiety, and social connectedness, linked to enhanced brain flexibility and serotonin pathways. However, older adults are notably underrepresented in psychedelic exploration, creating critical gaps in understanding optimal dosing, safety profiles, and long-term outcomes for this demographic. Tailored protocols are essential given age-related physiological changes and potential drug interactions.
Abstract
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental ...
The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience
Journal of Clinical Psychopharmacology – December 09, 2025
Summary
The intensity of a psilocybin experience is overwhelmingly driven by the dose, not individual traits. In a trial involving 233 participants battling treatment-resistant depression, those receiving 25, 10, or 1 mg of COMP360 psilocybin showed that the drug amount was the most consistent predictor of their subjective journey. While factors like positive affect or lower anxiety symptoms had minor influences on specific aspects, they were dwarfed by the administered dose. This challenges assumptions about personal characteristics dictating acute psychedelic effects, underscoring dose as the primary determinant.
Abstract
Purpose/Background: The therapeutic effects of psilocybin treatment are thought to be influenced by the subjective dose-dependent psychedelic exper...
THE ROLE OF PHARMACEUTICAL CARE IN THE THERAPEUTIC USE OF KETAMINE
Zenodo (CERN European Organization for Nuclear Research) – December 08, 2025
Summary
Pharmaceutical care plays a crucial role in the safe use of ketamine, especially during its therapeutic applications for major depression. An analysis of 50 studies revealed that while ketamine is effective for treatment, it carries risks, including adverse effects like dissociation and increased blood pressure in up to 30% of patients. Pharmacists can significantly enhance patient safety by monitoring these effects and providing guidance on proper dosage and adherence. This support is vital, particularly in the context of healthcare challenges faced during the COVID-19 pandemic.
Abstract
The present work aims to analyze the role of pharmaceutical care in the therapeutic use of ketamine, considering its clinical applications, risks, ...